NZ Liver Cancer Research Review Issue 2
In this issue:
– Atezolizumab + bevacizumab in unresectable HCC (CHALLENGE)
– Adjuvant chemotherapy or chemoradiation in gallbladder cancer (ACCELERATE)
– Nivolumab + ipilimumab vs lenvatinib or sorafenib for unresectable HCC (CheckMate 9DW)
– SBRT + sorafenib in HCC (NRG Oncology/RTOG 1112)
– TACE combined with lenvatinib + pembrolizumab for unresectable HCC (LEAP-012)
– Modifiable risk factors for HCC in patients with MASLD
– Risk of HCC by steatotic liver disease and its subclassifications
– Disease aetiology does not affect atezolizumab + bevacizumab efficacy in HCC
– Use of GALAD score for detection of HCC in cirrhosis
– NC-AMRI versus ultrasound as surveillance modalities for HCC
Expert contributor
Dr Jeffrey Ngu
Dr Jeffrey Ngu (MB ChB, FRACP, PhD) is a consultant gastroenterologist and hepatologist at Christchurch Hospital and a senior lecturer at the University of Otago, Christchurch. His research interests include autoimmune liver diseases, MASLD, viral hepatitis and gastrointestinal haemorrhage.
Expert contributor
Dr Nikki Burnand
Nikki is a general medical oncologist, currently practicing in Wellington Regional Hospital. Her main sub interest is gastrointestinal cancers. Nikki is a Clinical Senior Lecturer at the University of Otago School of Medicine.
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.
